Table 4

Induction of CEA-specific T cells in HLA-A2-positive patients immunized with ALVAC-CEA-B7.1

ALVAC-CEA-B7.1 was injected at three dose levels (2.5 × 107 pfu, 1.0 × 108 pfu, and 4.5 × 108 pfu). Patients were vaccinated on days 1, 14, 28, and 42. Results are expressed as a precursor frequency of IFN-γ-secreting cells. PBMCs from HLA-A2-positive patients from baseline and after four vaccinations (post) were used as effector cells.

Patient no.Treatment (pfu)SampleFlu spots/ 5 × 105Flu precursor frequencyRatio of post:pre (Flu)CEA spots/ 5 × 105CEA precursor frequencyRatio of post: pre (CEA)
22.5 × 107Baseline31 /166,6661.3≤2<1 /200,000≥1.6
Post41 /125,00041 /125,000
41.0 × 108Baseline51 /100,0000.8≤2<1 /200,000≥4.0
Post41 /125,00081 /62,500
61.0 × 108Baseline121 /45,4540.961 /83,3333.5
Post101 /50,000211 /23,809
104.5 × 108Baseline3.61 /140,0001.04.31 /116,0001.3
Post3.61 /140,0005.71 /87,000
114.5 × 108Baseline7.91 /63,6360.93.61 /140,0002.1
Post9.31 /68,3338.61 /68,000
174.5 × 108Baseline7.91 /63,6361.2≤2<1 /200,000≤4.3
Post9.31 /53,84610.71 /46,666
184.5 × 108Baseline5.21 /19,2301.13.21 /31,2502.6
Post5.81 /17,2418.41 /11,904
204.5 × 108Baseline71 /71,0001.291 /55,5564.2
Post81 /62,000381 /13,157
264.5 × 108Baseline10.51 /31,2500.515.51 /32,2580.7
Post7.51 /66,66611.51 /43,478
274.5 × 108Baseline31 /166,6661.21.5<1 /200,000≥3.6
Post3.51 /142,85791 /55/555
284.5 × 108Baseline51.51 /9,7081.313.51 /34,4832.3
Post65.51 /7,633331 /15,151
304.5 × 108Baseline38.31 /33,3331.541 /125,0009.1
Post43.31 /22,22236.51 /13,698
344.5 × 108Baseline38.31 /13,0431.0≤2<1 /200,000≥14.3
Post43.31 /12,50030.81 /13,953
364.5 × 108Baseline23.41 /21,4291.76.71 /75,0003.8
Post39.21 /12,766251 /20,000
374.5 × 108Baseline10.91 /46,1531.34.21 /120,0003.2
Post14.21 /35,29413.41 /37,500